FDA red and green lights: April 2025
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
The month ahead: April’s upcoming events
AACR approaches, along with ASCO abstract titles.
ESMO 2024 – Keytruda/Lenvima leap... up to a point
Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.
Tempest’s pivotal amezalpat conundrum
How does the micro-cap biotech now finance a 700-patient phase 3 study?
ASCO 2024 – AstraZeneca’s GPC3 secret sauce
A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.
ASCO 2024 preview – new Car-T target shows liver cancer promise
Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.
